Indivior (NASDAQ:INDV) Shares Gap Down to $11.09

Indivior PLC (NASDAQ:INDV)’s stock price gapped down prior to trading on Friday . The stock had previously closed at $11.09, but opened at $10.66. Indivior shares last traded at $10.83, with a volume of 410,034 shares changing hands.

Analyst Ratings Changes

INDV has been the subject of a number of recent analyst reports. Piper Sandler initiated coverage on shares of Indivior in a research report on Tuesday, July 23rd. They issued an “overweight” rating and a $22.00 price objective for the company. Craig Hallum reduced their price objective on shares of Indivior from $37.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday, July 10th.

Indivior Stock Performance

The stock’s 50-day moving average is $12.46 and its 200 day moving average is $16.70. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.85 and a quick ratio of 0.68. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 1,035.00 and a beta of 0.68.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. Indivior had a negative net margin of 12.29% and a negative return on equity of 654.82%. The company had revenue of $299.00 million during the quarter, compared to the consensus estimate of $285.90 million. As a group, analysts predict that Indivior PLC will post 1.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INDV. Norges Bank acquired a new position in shares of Indivior during the 4th quarter worth approximately $36,011,000. UBS Group AG raised its position in shares of Indivior by 71.9% during the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock worth $12,615,000 after purchasing an additional 345,556 shares during the last quarter. Renaissance Group LLC raised its position in shares of Indivior by 6.1% during the 4th quarter. Renaissance Group LLC now owns 103,023 shares of the company’s stock worth $1,573,000 after purchasing an additional 5,896 shares during the last quarter. Campbell & CO Investment Adviser LLC grew its stake in Indivior by 2.8% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 37,948 shares of the company’s stock worth $573,000 after acquiring an additional 1,037 shares during the period. Finally, Premier Fund Managers Ltd grew its stake in Indivior by 17.8% in the 4th quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company’s stock worth $12,901,000 after acquiring an additional 128,611 shares during the period. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.